Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference
03 Marzo 2021 - 3:35PM
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage
drug discovery company developing pharmacologically active drugs
for use in cancer treatment, will participate in the virtual 33rd
Annual Roth Conference, being held March 15-17,
2021. Investors may register and consult the conference agenda
at the event website.
A webcast of Lixte’s investor presentation by
Founder and Chief Executive Officer John S. Kovach, M.D. will be
available on demand at the event website and at Lixte’s website
under Investor Information: News & Events. A replay of the
webcast will be available on the Company's website for 12 months
following the conference.
During the corporate presentation and in
one-on-one and small group investor meetings, Dr. Kovach will
discuss the Company’s proprietary clinical stage compound LB-100, a
first in-class protein phosphatase (PP2A) inhibitor that increases
the anti-tumor activity of standard chemotherapy, radiotherapy, and
immunotherapy without increasing toxicity. LB-100 is initially
being evaluated in three clinical treatment studies (phase 1b/2 for
Myelodysplastic Syndromes, Advanced Soft Tissue Sarcoma, and Small
Cell Lung Cancer and in a phase 0 (human
pharmacodynamic/pharmacokinetic study) in recurrent gliomas. LB-100
is also being tested for potential benefit in a rodent model of
Angelman Syndrome, a severe neurodevelopmental disorder. There are
no direct competitors of LB-100 known to Lixte in the clinic at
present.
Dr. Kovach commented, “LB-100 causes cancer
cells, injured by chemo or radiotherapy, to continue to replicate
before repairing their injuries, leading to more efficient cancer
cell killing by many standard anti-cancer regimens. If the
improvement of standard treatments for diverse cancers by LB-100 is
documented in the clinic, our first-in-class compound will be a
game-changing advance in cancer therapy worldwide.”
About Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXT)
is a clinical-stage pharmaceutical company dedicated to discovering
drugs for more effective treatments for many forms of cancer and
other serious common diseases. A major driver of cancer is defects
in the switches that turn the biochemical pathways in cells on and
off. Most cancer research over the past 30 years has focused on the
“on” switches because the “off” switches, especially the master
“off” switch protein phosphatase (PP2A), were believed to cause
intolerable toxicity in patients. Lixte has achieved a breakthrough
with its novel, first-in-class lead compound, PP2A inhibitor
LB-100, by demonstrating that it is readily tolerated in cancer
patients at doses associated with anti-cancer activity. This
innovative approach encourages cancer cells, damaged by chemo or
other cancer therapies, to continue to replicate before repairing
the damage, leading to the more efficient death and elimination of
those cells from the body. Lixte has partnered with top
medical institutions and leading academic research centers to
advance the clinical development of its compounds. The LB-100
compound, of which there are no competitors known to Lixte, is
being tested in three clinical cancer treatment studies with others
in planning. lixte.com
Forward-Looking Statements
This announcement contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, and Section 21E of the Securities Exchange
Act of 1934. For example, statements regarding the Company's
financial position, business strategy and other plans and
objectives for future operations, and assumptions and predictions
about future product demand, supply, manufacturing, costs,
marketing and pricing factors are all forward-looking statements.
These statements are generally accompanied by words such as
"intend," anticipate," "believe," "estimate," "potential(ly),"
"continue," "forecast," "predict," "plan," "may," "will," "could,"
"would," "should," "expect" or the negative of such terms or other
comparable terminology. The Company believes that the assumptions
and expectations reflected in such forward-looking statements are
reasonable, based on information available to it on the date
hereof, but the Company cannot provide assurances that these
assumptions and expectations will prove to have been correct or
that the Company will take any action that the Company may
presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar
businesses, and market and general economic factors. This
discussion should be read in conjunction with the Company's filings
with the United States Securities and Exchange Commission
at http://www.sec.gov/edgar.shtml.
Lixte Contact:info@lixte.comGeneral Phone:
(631) 830-7092Investor Phone: (888) 289-5533
Grafico Azioni Lixte Biotechnology (NASDAQ:LIXT)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Lixte Biotechnology (NASDAQ:LIXT)
Storico
Da Lug 2023 a Lug 2024